Pharmafile Logo
Pharmafocus logo
Advanced Search

Victoza

Showing 15 posts of 42 posts found.

novo_flag

FDA approves Novo Nordisk’s Victoza for children with type 2 diabetes

June 18, 2019
Manufacturing and Production GLP-1, Novo Nordisk, Victoza, diabetes, liraglutide

The FDA has approved Novo Nordisk’s Victoza (liraglutide) for paediatric patients aged 10 years and older with type 2 diabetes. …

News

Novo’s oral semaglutide beats Victoza and Januvia in diabetes

June 21, 2018
Research and Development Januvia, MSD, Novo Nordisk, Victoza, pharma, semaglutide

Novo Nordisk has released new data for its oral semaglutide diabetes therapy from two trials, showing that the GLP-1 analogue …

News
novo_flag

Novo Nordisk settles lawsuit over illegal marketing practices for $58.7 million

September 6, 2017
Research and Development, Sales and Marketing FDA, Novo Nordisk, US, US Justice Department, Victoza, diabetes, pharma, pharmaceutical

Novo Nordisk has resolved a probe by the US Justice Department which accused the Danish drugmaker of illegal marketing activities …

News

Novo Nordisk’s diabetes drug recommended for expanded indication in Europe

June 27, 2017
Research and Development, Sales and Marketing CHMP, EMA, EU, Novo Nordisk, Victoza

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has given its recommendation to expand the indication of Novo …

News
novo_nordisk_flag

FDA backs Novo’s diabetes drug for cardiovascular efficacy

June 21, 2017
Research and Development Novo Nordisk, Victoza

Good news for Novo Nordisk as the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the FDA recommends that data …

News

Novo Nordisk diabetes drug Victoza fails to reduce heart failure risk

August 5, 2016
Medical Communications, Research and Development Eli Lily, Novo Nordisk, Victoza, diabetes, heart failure

Novo Nordisk’s diabetes drug Victoza (liraglutide), which was found to cut cardiovascular risks in sufferers of heart disease, has failed …

News
novo_flag

Novo Nordisk says Victoza lowers risk of heart attacks in diabetes patients

June 14, 2016
Manufacturing and Production, Research and Development Novo Nordisk, Victoza, drug trial, type 2 diabetes

Danish diabetes drugmaker giant Novo Nordisk (NYSE: NVO) on Tuesday said a large study showed its Victoza (liraglutide) reduced the risk of …

News
novo_flag

FDA committee unanimously recommends Novo Nordisk diabetes combo, IDegLira

May 25, 2016
Research and Development, Sales and Marketing FDA, Novo Nordisk, Panel, Tresiba, Victoza, committee, ideglira, recommendation, staff

Novo Nordisk has announced that a US Food and Drug Administration (FDA) advisory committee has unanimously recommended IDegLira, a type-2 …

News
novo_flag

Novo says Victoza bests MSD’s Januvia at lowering blood sugar

April 4, 2016
Research and Development Novo Nordisk, Victoza

Novo Nordisk says its diabetes drug Victoza, in combination with metformin, outperformed MSD’s Januvia plus metformin in reducing HbA1c – …

News
novo_nordisk

Novo Nordisk reports five-year Victoza cardiovascular safety data

March 7, 2016
Research and Development, Sales and Marketing Novo Nordisk, Victoza

Novo Nordisk has announced the top-line results from a trial investigating the cardiovascular safety of Victoza (liraglutide [rDNA origin] injection) …

News
Victoza

Novo Nordisk buys Xoma diabetes program and scores trial successes

December 2, 2015
Research and Development, Sales and Marketing Novo Nordisk, Ryzodeg, SGLT2 inhibitors, Victoza, Xoma, diabetes

Novo Nordisk has announced its purchase of a type 2 diabetes diabetes program in a deal with biotech firm Xoma …

News
Victoza

Novo Nordisk looks to HEOR data to back Victoza

November 11, 2015
Research and Development, Sales and Marketing Byetta, HEOR, Lyxumia, NHS, Novo Nordisk, Victoza, cost-effectiveness

A Novo Nordisk-sponsored study of the cost-effectiveness of three different injectable anti-diabetes drugs has found Victoza is a cheaper option …

News

Jardiance scores more cardiovascular outcomes data

November 10, 2015
Manufacturing and Production Boehringer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Victoza, cardiovascular outcomes, diabetes, empagliflozin, jardiance, lilly, liraglutide, type 2 diabetes

A sub-group analysis of data from an outcomes study of Boehringer Ingelheim’s and Lilly’s Jardiance has found the diabetes drug …

News
novonordiskhq

Novo Nordisk abandons Victoza submission after mixed T1D results

August 26, 2015
Research and Development Novo Nordisk, Victoza, diabetes, insulin

Novo Nordisk has been forced to scrap plans to expand its licence for Victoza to include adults with type 1 …

News
Saxenda image

Novo Nordisk obesity drug gets EU approval

March 24, 2015
Sales and Marketing EMA, EU, FDA, Victoza, liraglutide, obesity, saxenda

Novo Nordisk’s obesity drug Saxenda has been approved by the European Commission for use across the EU. This approval follows …

News
The Gateway to Local Adoption Series

Latest content

Historic UN declaration supporting mental health – treatment to be given similar priority to chronic diseases

January 30, 2026

Rare diseases – spinal muscular atrophy

January 30, 2026

Could targeting the molecular causes of infertility finally transform IVF success rates?

January 29, 2026

Digital mental health technologies – a valuable tool in supporting people with depression and anxiety

January 29, 2026

Barts Health NHS Trust collaborates with H.I.G. Realty on healthcare innovation building

January 29, 2026